Published in Cancer Weekly, October 6th, 2009
"Because this particular D-type cyclin has been suggested to be a key mediator for ErbB2-associated mammary tumorigenesis, we deleted Jak2 from ErbB2-expressing mammary epithelial cells prior to tumor onset and in neoplastic cells to address whether this tyrosine kinase plays a role in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-10-06)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.